Circumventing tumor resistance to chemotherapy by nanotechnology
about
Anti-Cancer Properties of the Naturally Occurring Aphrodisiacs: Icariin and Its DerivativesThe Utilization of the Immune System in Lung Cancer Treatment: Beyond ChemotherapyEngineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.Toward precision medicine of breast cancerPLGA-loaded nanomedicines in melanoma treatment: Future prospect for efficient drug deliveryAntitumor Activity of a 5-Hydroxy-1H-Pyrrol-2-(5H)-One-Based Synthetic Small Molecule In Vitro and In VivoAn emerging interface between life science and nanotechnology: present status and prospects of reproductive healthcare aided by nano-biotechnologyNanodiamonds as novel nanomaterials for biomedical applications: drug delivery and imaging systems.Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective.'Green' biocompatible organic-inorganic hybrid electrospun nanofibers for potential biomedical applications.Evidence for induction of a tumor metastasis-receptive microenvironment for ovarian cancer cells in bone marrow and other organs as an unwanted and underestimated side effect of chemotherapy/radiotherapy.Flavonoids isolated from Citrus platymamma induced G2/M cell cycle arrest and apoptosis in A549 human lung cancer cellsMultistage vector (MSV) therapeutics.Cancer cell-selective killing polymer/copper combination.Mathematical Modelling and Analysis of the Tumor Treatment Regimens with Pulsed Immunotherapy and ChemotherapyCombination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivoGlaucarubinone sensitizes KB cells to paclitaxel by inhibiting ABC transporters via ROS-dependent and p53-mediated activation of apoptotic signaling pathways.Millepachine, a potential topoisomerase II inhibitor induces apoptosis via activation of NF-κB pathway in ovarian cancer.Synergistically enhanced selective intracellular uptake of anticancer drug carrier comprising folic acid-conjugated hydrogels containing magnetite nanoparticles.Recent trends in cancer drug resistance reversal strategies using nanoparticles.Nanomedicine as an emerging platform for metastatic lung cancer therapy.New hydrazonoindolin-2-ones: Synthesis, exploration of the possible anti-proliferative mechanism of action and encapsulation into PLGA microspheres.Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.Exploring and validating physicochemical properties of mangiferin through GastroPlus® software.Epigallocatechin gallate sensitizes cisplatin-resistant oral cancer CAR cell apoptosis and autophagy through stimulating AKT/STAT3 pathway and suppressing multidrug resistance 1 signaling.A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bulletComplex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.Liposome armed with herpes virus-derived gH625 peptide to overcome doxorubicin resistance in lung adenocarcinoma cell lines.Albendazole as a promising molecule for tumor control.Design and In Vitro Evaluation of Bispecific Complexes and Drug Conjugates of Anticancer Peptide, LyP-1 in Human Breast Cancer.Cancer resistance to treatment and antiresistance tools offered by multimodal multifunctional nanoparticles.Folic acid conjugation improves the bioavailability and chemosensitizing efficacy of curcumin-encapsulated PLGA-PEG nanoparticles towards paclitaxel chemotherapy.Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.Novel strategies to prevent the development of multidrug resistance (MDR) in cancer.Phytochemical based nanomedicines against cancer: current status and future prospects.Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.Structural Studies of Predicted Ligand Binding Sites and Molecular Docking Analysis of Slc2a4 as a Therapeutic Target for the Treatment of Cancer.A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin.ϵ-Polylysine-Capped Mesoporous Silica Nanoparticles as Carrier of the C9h Peptide to Induce Apoptosis in Cancer Cells.Antitumor activity of raloxifene-targeted poly(styrene maleic acid)-poly (amide-ether-ester-imide) co-polymeric nanomicelles loaded with docetaxel in breast cancer-bearing mice.
P2860
Q26738330-ADE77919-113F-40AF-B653-36D0789004ADQ28066568-E88CB5DB-0AD9-4EFE-804B-48F4DBA0B535Q28073956-E1833859-70CB-4666-A054-AECB60570A62Q28073967-13E4EE02-2558-46B6-8403-3BF3D90C5C09Q28076905-B515B9EC-3FE4-494C-B7EB-9F7A94937EEFQ28547861-2AFEF080-D9F0-41C7-947E-FD2E2D71E819Q28658189-A7B14F62-304C-489B-80CB-B076C7467485Q30459082-9A3692D6-17D4-4BAD-B728-2ECFB0846666Q33553453-23364EF8-5DE0-4FC7-AD4C-7BA758BBB025Q35236552-D9C850E5-C6FA-4C81-824F-AE476866D390Q35588508-27477922-CC40-4939-8AAA-D0AA2023A3F4Q36083514-43A80064-7E31-4FD6-BC8B-DA9EE53D92D0Q36307634-9F07B47A-ABB2-475B-8DD8-8FBF1AA7D4B6Q36372931-B058A3E9-597D-4BE9-A28D-CC9AB3011036Q36656344-67797617-DD9A-474C-8CB3-A7A3093553D3Q36657133-255E5158-C059-4C20-BF16-F8DF3C9DF326Q37520549-BDD00717-974C-48F0-8699-1E70C02CB4FAQ37588443-4D574FF5-7A9A-47CF-B24E-AB96F04564AAQ37595258-8FFDFA95-45F0-491F-99F4-877BCF30420EQ37984588-0D8209A2-AD1C-45C1-9B21-C1BE293984A6Q38463092-6E013D8D-C8E9-4FA9-859F-B643F1884345Q38696393-EF1D65D4-C04E-4706-87D1-E076336E579FQ38724921-8305F7A6-7EEF-47F8-9F44-3805EBE66B5CQ38739454-F9A1A2D6-F59A-4494-BFBD-3EB0292B3925Q38769690-68620EFA-D3BD-4228-8242-12960AC1A5B1Q39066797-EFA4BFAA-B5DB-4F78-8DBE-F3346EE2DA1FQ39458957-9537AA66-884E-4998-A567-3A9BBCD97D4EQ39996592-E5613415-4F09-4F00-805D-A5093BDBACEDQ41348862-46441C9E-71E8-40C7-9742-C6C8244CC04FQ45299208-7F48CFF5-DDD8-494F-B892-12AFD514E26AQ47093736-92A2E876-359A-4307-8D55-9BF0161FD1D1Q47106467-41374E1E-3A1E-48FD-832F-DD794E5A8223Q47119535-88BA7266-A782-4C8D-9028-EEC19998900CQ47129596-3FB06F55-5D69-4FF0-A231-3AAC5E7A99BAQ47829215-486A5076-6E80-46A9-868C-F7F343A5D8A2Q48012324-9B2F5349-E761-4995-8F1C-CEFD9CEAF8CBQ48043092-66E95BBC-BB84-4950-ADFF-883CE3CDCFEDQ48185664-7FC1D33E-C1A3-4D2A-A4F4-C2715E60EA15Q48202233-65F35F64-FA3E-4B84-94F7-4CDDB93BE468Q48234001-457175FE-D39F-4865-B33A-FDF470A64274
P2860
Circumventing tumor resistance to chemotherapy by nanotechnology
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Circumventing tumor resistance to chemotherapy by nanotechnology
@ast
Circumventing tumor resistance to chemotherapy by nanotechnology
@en
Circumventing tumor resistance to chemotherapy by nanotechnology
@nl
type
label
Circumventing tumor resistance to chemotherapy by nanotechnology
@ast
Circumventing tumor resistance to chemotherapy by nanotechnology
@en
Circumventing tumor resistance to chemotherapy by nanotechnology
@nl
prefLabel
Circumventing tumor resistance to chemotherapy by nanotechnology
@ast
Circumventing tumor resistance to chemotherapy by nanotechnology
@en
Circumventing tumor resistance to chemotherapy by nanotechnology
@nl
P2093
P2860
P1476
Circumventing tumor resistance to chemotherapy by nanotechnology
@en
P2093
Chunying Chen
Paul C Wang
Xing-Jie Liang
Yuliang Zhao
P2860
P304
P356
10.1007/978-1-60761-416-6_21
P407
P577
2010-01-01T00:00:00Z